CAS: 125552-89-8; 4-(Bromomethyl)Tetrahydropyran

相似化合物

4677-20-7 1262410-27-4 1936111-60-2

上下游产品

CAS号132291-95-3 (4-(羟基甲基)-四氢-2H... | CAS号14774-37-9 4-(羟甲基)四氢吡喃 | CAS号558-13-4 四溴化碳 | CAS号5337-03-1 四氢吡喃-4-甲酸 | CAS号110238-91-0 四氢吡喃-4-羧酸甲酯 | CAS号101691-65-0 (四氢吡喃-4-基)-4-甲基甲苯磺酸 | CAS号85064-61-5 四氢吡喃-4-乙酸 | CAS号850429-50-4 4-氰甲基四氢吡喃 | CAS号130290-79-8 4-氨甲基四氢吡喃 | CAS号1822-32-8 3-(4-哌啶基)丙酸 | CAS号40500-10-5 四氢-2H-吡喃-4-丙酸 | CAS号52601-24-8 1-azabicyclo[2....

(4-(羟基甲基)-四氢-2H-吡喃-4-基)甲烷磺酸盐置于lithium Bromide体系中,用 水,丙酮 用作溶剂,以81%的收率获得4-溴甲基四氢吡喃
参考文献:Pharmaceutical Compositions And Methods For Effecting Dopamine Release
标题:Pharmaceutical Compositions And Methods For Effecting Dopamine Release
摘要:患有或易受影响的病人,如中枢神经系统紊乱,其特征是正常神经递质释放的改变,如多巴胺释放(例如帕金森病,帕金森氏病,抽动症,注意力不足障碍或精神分裂症),可通过给予1-Aza-2-(3-吡啶基)双环[2.2.1]庚烷,1-Aza-2-(3-吡啶基)双环[2.2.2]辛烷,1-Aza-2-(3-吡啶基)双环[3.2.1]辛烷,1-Aza-2-(3-吡啶基)双环[3.2.2]壬烷,1-Aza-7-(3-吡啶基)双环[2.2.1]庚烷,1-Aza-3-(3-吡啶基)双环[3.2.2]壬烷或1-Aza-7-(3-吡啶基)双环[3.2.2]壬烷来治疗.这些化合物可以存在为单体立体异构体,消旋混合物,非对映异构体等形式.

专利信息

专利号:EP-1836163-B1
优先权日:2004-12-23
标题 :Pyrrolidine derivatives for the treatment of a disease depending on the activity of renin
发明人：BREITENSTEIN WERNER; COTTENS SYLVAIN; EHRHARDT CLAUS; JACOBY EDGAR; LORTHIOIS EDWIGE LILIANE JEANNE; MAIBAUM JUERGEN KLAUS; OSTERMANN NILS; SELLNER HOLGER; SIMIC OLIVER
权利人:NOVARTIS AG
摘要:Novel 3-mono-, 3,4-di- and 3,4,4,-tri-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on inappropriate activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on inappropriate activity of renin; the use of a compound of that class in the treatment of a disease that depends on inappropriate activity of renin; pharmaceutical formulations comprising a said substituted pyrrolidine compound, and/or a method of treatment comprising administering a said substituted pyrrolidine compound, a method for the manufacture of said substituted pyrrolidine compounds, and novel intermediates and partial steps for their synthesis are described. The substituted pyrrolidine compounds are especially of the formula I wherein the substituents are as described in the specification.

专利号:US-11286268-B1
优先权日:2019-07-02
标题:EIF4E-inhibiting compounds and methods
发明人：SPERRY SAMUEL; XIANG ALAN X; ERNST JUSTIN T; REICH SIEGFRIED H; SPRENGELER PAUL A; SHAGHAFI MIKE; MICHELS THEO; NILEWSKI CHRISTIAN; TRAN CHINH VIET; PACKARD Garrick Kenneth; GRUBBS ALAN; URKALAN KAVERI; MUKAIYAMA TAKASUKE
权利人:EFFECTOR THERAPEUTICS INC
摘要:The present invention provides synthesis, pharmaceutically acceptable formulations and uses of compounds in accordance with Formula I, or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof. n n n n n n n n n n For Formula I compounds X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , Q, L 1 , L 2 , Y, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and rings A, B and C are as defined in the specification. The inventive Formula I compounds are inhibitors of eIF4e and find utility in any number of therapeutic applications, including but not limited to treatment of inflammation and various cancers.